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The term “stroke” is applied to a heterogeneous group of diseases caused by decreased 
perfusion of the brain due to occlusion of the blood vessels supplying the brain or a 
haemorrhage originating in them. Most strokes (~ 85%) are ischemic; that is, they result 
from occlusion of a major cerebral artery by a thrombus or embolism. This results in 
reduced blood flow and a major decrease in the supply of oxygen and nutrients to the 
affected region. The rest of strokes are haemorrhagic: caused by the rupture of a blood 
vessel either in the brain or on its surface.  
Strokes deprive the brain not only of oxygen but also of glucose and of all other nutrients, as 
well as disrupting the nutrient/waste exchange process required to support brain 
metabolism. The result is the development of a hypoxic-ischemic state. Ischemia is defined 
as a decrease in blood flow to tissues that prevents adequate delivery of oxygen, glucose 
and others nutrients. Ischemic stroke is the result of total or partial interruption of cerebral 
arterial blood supply, which leads to oxygen and glucose deprivation of the tissue 
(ischemia). If cerebral arterial blood flow is not restored within a short period, cerebral 
ischemia is the usual result, with subsequent neuron death within the perfusion territory of 
the vessels affected. Ischemic stroke is characterized by a complex sequence of events that 
evolves over hours or even days [1-3]. Acute ischemic stroke results from acute occlusion of 
cerebral arteries. Cerebral ischemia occurs when blood flow to the brain decreases to a level 
where the metabolic needs of the tissue are not met. Cerebral ischemia may be either 
transient (followed by reperfusion) or essentially permanent. In all cases, a stroke involves 
dysfunction and death of brain neurons and neurological damage that reflects the location 
and size of the brain area affected [1, 2]. 
2. Ischemic core and ischemic penumbra 
Neuropathological analysis after focal brain ischemia reveals two separate areas: the 
ischemic core, and ischemic penumbra. Once onset of a stroke has occurred, within 
minutes of focal ischemia occurring, the regions of the brain that suffer the most severe 
degrees of blood flow reduction experience irreversible damage: these regions are the 
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“ischemic core”. This area exhibits a very low cerebral blood flow (CBF) and very low 
metabolic rates of oxygen and glucose [2, 3]. Thus, reduced or interrupted CBF has 
negative effects on brain structure and function. Neurons in the ischemic core of the 
infarction are killed rapidly by total bioenergetic failure and breakdown of ion 
homeostasis, lipolysis and proteolysis, as well as cell membrane fragmentation [4]. The 
result is cell death within minutes [5]. Tissue in the ischemic core is irreversibly injured 
even if blood flow is re-established. 
The necrotic core is surrounded by a region of brain tissue which suffers moderate blood 
flow reduction, thus becoming functionally impaired but remaining metabolically active; 
this is known as the “ischemic penumbra” [6]. This metabolically active border region 
remains electrically silent [7]. From experiments in non-human primates, it has been shown 
that in this region, the ability of neurons to fire action potentials is lost. However, these 
neurons maintain enough energy to sustain their resting membrane potentials and when 
collateral blood flow improves, action potentials are restored. The ischemic penumbra may 
comprise as much as half the total lesion volume during the initial stages of ischemia, and 
represents the region in which there is an opportunity to salvage functionality via post-
stroke therapy [8, 9]. 
Ischemic penumbra refers to the region of brain tissue that is functionally impaired but 
structurally intact; tissue lying between the lethally damaged core and the normal brain, 
where blood flow is sufficiently reduced to result in hypoxia that is severe enough to arrest 
physiological function, but not so complete as to cause irreversible failure of energy 
metabolism and cellular necrosis [8]. The ischemic penumbra has been documented in 
laboratory animals as severely hypoperfused, non-functional, but still viable brain tissue 
surrounding the irreversibly damaged ischemic core [10]. The penumbra can be identified 
by the biochemical and molecular mechanisms of neuron death [11, 12] and by means of 
clinical neuroimaging tools [10, 13]. 
Thus, the ischemic penumbra refers to areas of the brain that are damaged during a stroke 
but not killed. The concept therefore emerges that once onset of a stroke has begun, the 
necrotic core is surrounded by a zone of less severely reduced blood flow where the 
neurons have lost functional activity but remain metabolically active. Tissue injury in the 
ischemic penumbra is the outcome of a complex series of genetic, molecular and 
biochemical mechanisms, which contribute either to protecting –and then penumbral 
tissue is repaired and recovers functional activity– or to damaging –and then the 
penumbral area becomes necrotic –brain cells. Tissue damage and functional impairment 
after cerebral ischemia result from the interaction between endogenous neuroprotective 
mechanisms such as anti-excitotoxicity (GABA, adenosine and KATP activation), anti-
inflammation and anti-apoptosis (IL-10, Epo, Bcl-proteins), and repair and regeneration 
(c-Src formation, vasculogenesis, neurogenesis, BM-derived cells) on the one hand, with 
neurotoxic events such as excitotoxicity, inflammation and apoptosis that ultimately lead 
to cell death, on the other [14]. The penumbra is the battle field where the ischemic 
cascade with several deleterious mechanisms is triggered, resulting in ongoing cellular 
injury and infarct progression. Ultimately, the ischemic penumbra is consumed by 
progressive damage and coalesces with the core, often within hours of the onset of the 
stroke. However, the penumbra can be rescued by improving the blood flow and/or 
interfering with the ischemic cascade. At the onset of a stroke, the evolution of the 
ischemic penumbra is only partially predictable from the clinical, laboratory and imaging 
methods currently available [3, 10]. 
www.intechopen.com
 
Excitotoxicity and Oxidative Stress in Acute Ischemic Stroke 
 
31 
3. Pathophysiological basis of the stroke 
In the last 30 years, experimental and clinical results have led to characterizations of the 
pathophysiological basis of strokes [1-3]. Cerebral ischemia (ischemic stroke) triggers a 
complex series of physiological, biochemical, molecular and genetic mechanisms that impair 
neurologic functions through a breakdown of cellular integrity mediated by ionic 
imbalance, glutamate-mediated excitotoxicity and also such phenomena as calcium 
overload, oxidative stress, mitochondrial dysfunction and apoptosis [1-3, 15, 16]. These 
mediate injury to neurons, glia cells and vascular elements by means of disturbing the 
function of important cellular organelles such as mitochondria, nuclei, cell membranes, 
endoplasmic reticula and lysosomes. The result is cell death via mechanisms that promote 
rupture, lysis, phagocytosis or involution and shrinkage [11, 16]. Knowledge of the 
molecular mechanisms that underlie neuron death following a stroke is important if we are 
to devise effective neuroprotective strategies. 
We will examine how ischemic injury occurs, which cell death mechanisms are activated, 
especially excitotoxicity and oxidative stress, and how these can be manipulated to induce 
neuroprotection. Unfortunately, despite their effectiveness in preclinical studies, a large 
number of neuroprotectants have failed to produce the desired effects in clinical trials 
involving stroke sufferers, which suggests that we still lack essential knowledge of the 
triggers and mediators of ischemic neuron death. We will discuss why, after 30 years or so 
of intense basic and clinical research, we still find it extremely difficult to translate 
experimental neuroprotective success in the laboratory to the clinical setting [17-20]. 
3.1 Acute ischemic injury in strokes 
Acute ischemic injury is the result of a transient or permanent reduction of CBF in a 
restricted vascular territory. Normal CBF is between 45 and 60 ml blood/100 g/min. It is 
well documented that time-dependent neuronal events are triggered in response to reduced 
CBF [21, 22]. The brain has critical thresholds for CBF and for oxygen tension. Oxygen 
supply to the brain below a critical level reduces, and eventually blocks, oxidative 
phosphorylation, drastically decreases cellular ATP and leads to the collapse of ion 
gradients. Neuron activity ceases and if oxygen is not re-introduced quickly, cells die [22]. A 
reduction of cortical blood flow to levels of approximately 20 ml/100 g/min may be 
tolerated without functional consequences, but it is associated with the loss of consciousness 
and ECG alterations. At values of CBF below 18 ml/100 g/min, the tissue infarction is time 
dependent: CBF of 5 ml/100 g/min lasting about 30 minutes cause infarction; CBF of 10 
ml/100 g/min needs to last for more than 3 hours to cause infarction; permanent CBF below 
18 ml/100 g/min causes irreversible damage [22, 23]. In focal ischemia, complete cessation 
of blood flow is uncommon because collateral vessels sustain CBF at 5 to 15 ml/100 
g/minute in the ischemic core and at 15 to 25 ml/100 g/minute in the outer areas of the 
ischemic zone [5, 21, 24]. Global ischemia results from transient CBF below 0.5 ml/100 
g/min or severe hypoxia to the entire brain. When CBF falls to zero within seconds, loss of 
consciousness occurs after approximately 10 s, EEG activity ceases after 30–40 s, cellular 
damage is initiated after a few minutes, and death occurs within 10 min, at least under 
normothermic conditions [25]. 
The brain is highly vulnerable to ischemia. In part, the vulnerability of brain tissue to 
ischemia reflects its high metabolic demands. The brain has a relatively high energy 
production demand and depends almost exclusively on oxidative phosphorylation for 
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energy production. Although the weight of the human brain is only about 2% of the total 
bodyweight, it has high metabolic activity and uses 20% of the oxygen and 25% of the 
glucose consumed by the entire body [23]. Proper functioning of brain cells depends on an 
abundant and continuous supply of oxygen. Even with such high metabolic demands, there 
is essentially no oxygen storage in cerebral tissue, and only limited reserves of high-energy 
phosphate compounds and carbohydrate substrates are available. More than 90% of the 
oxygen consumed by the brain is used by mitochondria to generate ATP. Energy in the 
brain is mainly formed when glucose is oxidized to CO2 and water through mitochondrial 
oxidative phosphorylation. At rest, about 40% of cerebral energy is used to maintain and 
restore ionic gradients across cell membrane; even more energy is used during activity [23]. 
The brain requires large amounts of oxygen to generate sufficient ATP to maintain and 
restore ionic gradients.   
3.2 Basic mechanisms of ischemic cell death 
After the onset of a stroke, the disruptions to the blood flow in areas affected by vascular 
occlusion limit the delivery of oxygen and metabolic substrates to neurons causing ATP 
reduction and energy depletion. The glucose and oxygen deficit that occurs after severe 
vascular occlusion is the origin of the mechanisms that lead to cell death and consequently 
to cerebral injury. These mechanisms include: ionic imbalance, the release of excess 
glutamate in the extracellular space, a dramatic increase in intracellular calcium that in turn 
activates multiple intracellular death pathways such as mitochondrial dysfunction, and 
oxidative and nitrosative stress that finally cause neuron death. 
After ischemic onset, the primary insult that ischemia causes neurons is a loss of oxygen and 
glucose substrate energy. While there are potentially large reserves of alternatives substrates 
to glucose, such as glycogen, lactate and fatty acids, for both glycolysis and respiration, 
oxygen is irreplaceable in mitochondrial oxidative phosphorylation, the main source of ATP 
in neurons. Consequently, the lack of oxygen interrupts oxidative phosphorylation by the 
mitochondria and drastically reduces cellular ATP production, which results in a rapid 
decline in cellular ATP [26, 27]. Although there are potentially large reserves of substrates 
such as glycogen, lactate and fatty acids that may be alternatives to glucose, anaerobic 
metabolism is insufficient to produce sufficient ATP. Reduced ATP stimulates the glycolytic 
metabolism of residual glucose and glycogen, causing an accumulation of protons and 
lactate, which leads to rapid intracellular acidification and increases the depletion of ATP 
[26]. When the lack of oxygen is severe and glucose is diminished, inhibition of oxidative 
phosphorylation leads to ATP-synthase functioning backwards and consuming ATP, thus 
contributing to an increase in the loss of ATP [27]. If ATP levels are low, the Na+/K+-ATPase 
function fails [27]. After several minutes, inhibition of the Na+/K+-ATPase function causes a 
profound loss of ionic gradients and the depolarization of neurons and astrocytes [28]. 
Membrane depolarization and changes in the concentration gradients of Na+ and K+ across 
the plasma membrane result in activation of voltage-gated calcium channels. This leads to 
excessive release of excitatory amino acids –particularly glutamate– to the extracellular 
compartment (Fig. 1). 
Uncontrolled membrane depolarization by massive changes in the concentration gradients of 
Na+ and K+ across the plasma membrane results in a large and sustained release of glutamate 
and other neurotransmitters to the extracellular compartment [29]. Simultaneously, 
neurotransmitter re-uptake from the extracellular space is reduced [30, 31]. The rise in the 
extracellular glutamate concentration initiates a positive feedback loop, with further activation 
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of glutamate receptors in neighbouring neurons and as a result, more Na+ inflow to neurons 
via monovalent ion channels that decrease ionic gradients and consume ATP, both of which 
promote further release of glutamate [32, 33]. Simultaneously, glutamate transporters in 
neurons and astrocytes can function backwards, releasing glutamate into the extracellular 
space [31, 34] and contributing to glutamate overload there. A marked and prolonged rise in 
the extracellular glutamate concentration kills central neurons [2, 11, 32]. Excessive glutamate 
in the synapses activates the ionotropic glutamate receptors at a pathophysiological level; this 
type of neuronal insult is called excitotoxicity [29] and is defined as cell death resulting from 
the toxic actions of excitatory amino acids. Because glutamate is the most important excitatory 
neurotransmitter in primary perception and constitutes the basis of synaptic transmission in 
about 1014 synapses in the human brain, neuronal excitotoxicity usually refers to the injury and 
death of neurons arising from prolonged intense exposure to glutamate and the associated 
ionic imbalance in the cell. Excessive activation of glutamate receptors by excitatory amino 
acids leads to a number of deleterious consequences, including impairment of calcium 
buffering, generation of free radicals, activation of the mitochondrial permeability transition 
and secondary excitotoxicity. 
 
 
Fig. 1. Excitotoxicity in ischemic stroke. The reduction of blood flow supply to the brain 
during ischemic stroke results in oxygen and glucose deprivation and thus a reduction in 
energy available to maintain the ionic gradients. This results in excessive neuronal 
depolarization and deregulated glutamate release.   
3.3 Excitotoxic mechanisms 
Excitotoxicity is considered to be the central mechanism underlying neuron death in stroke 
[29, 32-35]. Excitotoxicity is considered to trigger tissue damage in both focal experimental 
ischemia [34, 36] and clinical ischemia [37]. Glutamate is released at high concentrations in 
the penumbral cortex [38], particularly if blood flow is reduced for a long period, and the 
amount of glutamate released correlates with early neurological deterioration in patients 
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with acute ischemic stroke [37]. Glutamate concentrations greater than 200 mmol/l in 
plasma and greater than 8.2 mmol/l in CSF are associated with neurological deterioration in 
the acute phase of cerebral infarction.  
The excitotoxic mechanisms which lead to neuron death are complex, but primarily involve 
the generation of free radicals [35; 39, 40], mitochondrial dysfunction [41, 42] and the 
participation of various transcription factors as activators of gene expression [43, 44]. All of 
these mechanisms acting synergistically can damage cellular proteins [45], lipids [46] and 
DNA [47, 48], which leads to the deterioration of cellular architecture and signalling, 
resulting in necrosis, apoptosis or both depending on the severity of the insult and of 
relative speed of each process [49-51]. 
3.4 The role of glutamate receptors in excitotoxicity 
The excitatory effects of glutamate are mediated through two kinds of glutamate receptors –
ionotropic receptors and metabotropic receptors linked to G-protein [52]– found in the pre- 
and post-synaptic neuron membranes of the central nervous system (CNS). Glutamate 
ionotropic receptors are ligand-gated cation channels permeable to Ca2+. Although virtually 
all members of the glutamate receptor family are believed to be involved in mediating 
excitotoxicity [90], N-methyl-d-aspartate (NMDA) glutamate receptors are believed to be the 
key mediators of death during excitotoxic injury [53]. 
In recent years, the role of the structure of the NMDA glutamate receptors (NMDARs) in 
excitotoxicity has caused great therapeutic interest. NMDARs are complex heterotetramer 
combinations of three major subfamilies of subunits: the ubiquitously expressed NR1 
subunit together with one of the four possible NR2 (A-D) subunits and, in some cases, two 
NR3 (A and B) subunits [54, 55]. Subunit NR1 contains the site where the glutamate is 
united to the receptor, whereas subunit NR2 contains the site where the glycine is united 
[56]. The NR3 subunit is present predominantly during brain development [57]. The distinct 
pharmacological and biophysical properties mediated by NMDARs are largely determined 
by the type of NR2 subunits incorporated into the heteromeric NR1/NR2 complex [58, 59]. 
Specific NR2 subtypes appear to play a pivotal role in strokes [60]. In a four-vessel occlusion 
model of transient global ischemia in rats, the blocking of NMDARs that contained NR2A 
enhanced neuron death and prevented the induction of ischemic tolerance, whereas 
inhibiting NMDARs that contained NR2B attenuated ischemic cell death and enhanced 
preconditioning-induced neuroprotection [61]. It has been suggested that excitotoxicity is 
triggered by the selective activation of NMDARs containing the NR2B subunit [61, 62] and a 
correlation between NR2B expression, a rise in cytosolic calcium and excitotoxicity was 
observed in cortical neurons [63]. Because NR2A and NR2B are the predominant NR2 
subunits in the adult forebrain, where stroke most frequently occurs, NMDA receptors that 
contain NR2A and NR2B may play different roles in supporting neuronal survival and 
mediating neuron death, and hence have opposing impacts on excitotoxic brain damage 
after acute brain insults such as a stroke or brain trauma [60, 61]. 
NMDARs are found at synaptic or extrasynaptic sites [64, 65]. These different locations on 
cellular membrane have been considered a determining factor in excitotoxicity after a stroke 
[65, 66]. Depending on their location on the cell membrane, activation of NMDARs has 
dramatically different effects. Evidence suggests that synaptic NMDAR activity is necessary 
for neuronal survival while the extrasynaptic NMDARs are involved in cell death [65, 66]. 
Stimulation of synaptic NMDARs leads to expression of pro-survival proteins, such as 
BDNF (brain-derived neurotrophic factor) whereas activation of extrasynaptic NMDARs 
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leads to expression of pro-apoptotic proteins and suppression of survival pathways [64,65, 
67]. However, it has also been postulated that the apparent differences in excitotoxicity 
mediated by NMDARs could be due to differences in synaptic/extrasynaptic NMDAR 
molecular composition as opposed to the location of the receptors per se. In adults brain, 
NMDARs located in synapses predominantly contain the NR2A subtype; while 
extrasynaptic NMDARs predominantly contain NR2B [67-69]. Although there is little 
evidence that differences in subunit composition explain the differences between the 
synaptic and extrasynaptic effects of glutamate, a recent study showed that activation of 
NMDARs containing NR2B subunits tends to promote neuron death, irrespective of 
location, whereas activation of NMDARs containing NR2A subunits promotes survival [66]. 
However, have been shown that NR2A-NMDARs are capable of mediating excitotoxicity 
[70] and NR2B-NMDARs are capable of mediating both pro-survival and pro-death 
signalling, depending on the stimulation paradigm [69].  
It has further been proposed that lethal Ca2+ signalling by NMDARs is determined by the 
molecules with which they interact [85]. At the synapse, NMDAR receptors are found 
localized within electron-dense structures known as the postsynaptic densities (PSDs) 
where they form large and dynamic multiprotein signalling complexes [71-73]. NMDARs 
interact with multiple intracellular synaptic and cytoskeletal proteins, mainly through the 
cytoplasmatic C-termini of the NR1 and NR2 subunits [74, 75]. The PSD is a multiprotein 
complex that includes a group of proteins called MAGUKs (membrane-associated 
guanylate kinases) [74-76]. These proteins contain several PDZ (post-synaptic density-
95/discs large/zonula occludens-1) protein interaction domains through which they are 
connected to other proteins. PDZ is a common structure domain of 80-90 amino acids 
found in the signalling proteins. PDZ domains often function as modules in scaffolding 
proteins that are involved in assembling large protein complexes in the cell [73]. A 
prominent protein component in the PDZ complex is post-synaptic density-95 (PSD-95) 
[74, 75], which couples NMDARs to intracellular proteins and signalling enzymes. It also 
functions as a scaffolding and organizer protein of PSD [75, 76]. PSD-95 contains three 
PDZ domains, of the which the first two (PDZ1 and PDZ2) interact with the C termini of 
the NMDAR NR2B subunit. The NMDAR is linked to nNOS through the first and second 
PDZ domains of PSD-95 [76, 77]. Activation of the nNOS by NMDARs leads to the 
production of excessive levels of nitric oxide (NO) [71]. NO serves as a substrate for the 
production of highly reactive free radicals such as peroxynitrites, which promote cellular 
damage and ultimately neuron death [78-80]. Thus, during ischemia, Ca2+ influx through 
NMDARs promotes cell death more efficiently than through other Ca2+ channels [81], 
suggesting that proteins responsible for Ca2+-dependent excitotoxicity reside within the 
NMDAR signalling complex. Disrupting the NMDAR-PSD-95 or nNOS-PSD-95 complexes 
may reduce the efficiency by which Ca2+ ions activate excitotoxic signalling through 
molecules such as nNOS. In cortical neurons, suppression of PSD-95 selectively blocks NO 
production by NMDARs without affecting NOS expression [71]. In cultured neurons and 
in experimental animals, through the use of small peptides that disrupted the interaction 
of NMDARs with PSD-95, neurons were rendered resistant to focal cerebral ischemia [82]. 
It has been shown that inhibition of the NMDAR/PSD-95 interaction prevents ischemic 
brain damage, while the physiological function of the NMDAR remains intact [83]. The 
use of small peptides that bind to the PDZ domains of PSD-95 and block protein-protein 
interactions protected cultured neurons from excitotoxicity and dramatically reduced 
cerebral infarction in rats subjected to transient focal cerebral ischemia, and effectively 
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improved their neurological function. The treatment was effective when applied either 
before, or 1 h after, the onset of excitotoxicity in vitro and cerebral ischemia in vivo [83]. 
Perturbing NMDAR/PSD-95 interactions with peptides that comprise the nine C-terminal 
residues of the NR2B subunit reduces the vulnerability of neurons to excitotoxicity and 
ischemia. Proteomic and biochemical analysis of all the known human PDZs with 
synaptic signalling proteins that include NR1 or NR2A-NR2D, shows that only neurons 
lacking PSD-95 or nNOS exhibited reduced excitotoxic vulnerability. Of all the PDZs 
examined, only PSD-p5 and nNOS participated significantly in excitotoxicity signalling. 
Thus, despite the ubiquity of proteins that contain the PDZ domain, the importance of the 
role of PSD-95 and nNOS over and above that of any other PDZ proteins in mediating 
NMDAR-dependent excitotoxicity was recently demonstrated [70]. Deletion of the PSD-95 
dissociates NMDAR activity from NO production and suppresses excitotoxicity [84]. 
It remains an open question whether the death of neurons is mediated by different types of 
NMDAR subunits [66, 68] or only by distinct locations of the receptors [64, 65]. It is possible 
that Ca2+ toxicity is linked to the route of Ca2+ entry and the different second messenger 
pathways activated by Ca2+ entry [85]. 
Perhaps consideration of the NMDARs as the route to excitotoxicity is over-simplistic, since 
others mechanisms may be involved [86]. AMPA receptors are not normally calcium 
permeable due to their GluR2 subunit, nevertheless, after ischemia this subunit is reduced 
and the permeability of these receptors by calcium increases 18-fold, allowing AMPARs to 
contribute to increased intracellular calcium [87]. As just mentioned, injury during stroke 
may result from Ca2+-overload due to overstimulation of AMPA receptors together with 
indirect Ca2+ entry through gated voltage-channels, Ca2+-permeable acid-sensing ion 
channels [88], activation of metabotropic glutamate receptors via the release of Ca2+ from 
endoplasmic reticulum and via a cleavage of Na+/ Ca2+ exchangers [89]. Consequently, it 
seems that in relation to the mechanisms that mediate cell death in stroke, the more 
important factor is the amount of cytosol Ca2+ free to accumulate and not the route of entry. 
3.5 Ca
2+
 cytoplasmic overload, mitochondria dysfunction and oxidative stress 
After a stroke, as a consequence of excessive extracellular glutamates, NMDARs are 
excessively activated resulting in increased Ca2+ influx [35, 81, 84]. Calcium plays a critical 
role in the excitotoxic cascade, because either removing Ca2+ from extracellular medium 
[90] or preventing Ca2+ from entering mitochondria by uncouplers [91] protects neurons 
against excitotoxic injury. There is strong evidence that perturbed cellular Ca2+ 
homeostasis is pivotal in the death of neurons following a stroke [35, 81, 84, 92]. It is now 
well established that a strong relationship exists between excessive Ca2+ influx and 
glutamate-triggered neuronal injury during stroke [2, 43, 93]. The earliest studies of the 
mechanisms resulting in neuron death as a consequence of glutamate excitotoxicity 
established the essential role of calcium in neuron cell death resulting from excessive 
NMDAR activation [93-95]. Sustained overstimulation of NMDARs leads to Ca2+ and Na+ 
overload in postsynaptic neurons [92, 94, 95]. After ischemia, cytoplasmic Ca2+ levels rise 
to 50-100 µM. Such excessive Ca2+ levels can trigger many downstream neurotoxic 
cascades [35, 92, 94, 95], including the activation and overstimulation of proteases, lipases, 
phosphatases and endonucleases (Fig. 2). The results include the activation of several 
signalling pathways, mainly causing an overproduction of free radicals, dysfunction of 
mitochondria, cell membrane disruption, and DNA fragmentation, which acting 
synergistically cause neuron death [1, 2, 11, 84, 96]. 
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Fig. 2. Effects of very high Ca2+ accumulation in neurons after ischemia. Excitotoxicity 
causes a sudden increase in cytoplasmic Ca2+ concentrations in neurons after ischemia, 
which induces activation of several signaling pathways, leading to apoptototic or necrotic 
neuronal death. Activation of calpains, caspases, other proteases, kinases and 
endonucleases, cause mitochondrial disturbance, overproduction of free radicals and DNA 
fragmentation, that synergistically lead to neuronal death. 
Major excitotoxic events promoted by cytoplasmic Ca2+ overload due to massively activated 
glutamate receptors include mitochondrial dysfunction, oxidative/nitrosative stress and 
calpain activation (Fig. 3). 
The excitotoxicity can contribute to neuron death by altering the functions of mitochondria. 
Mitochondrial disturbance is the result of both oxidative-nitrosative stress and a direct effect of 
excessive Ca2+ intracellular levels. Mitochondrial dysfunction is caused by free radicals and the 
mitochondrial disturbance, in turn, increases the production of free radicals. Mitochondria 
play an important role in calcium homeostasis [97, 98]. Under conditions of cytoplasmic excess 
of Ca2+, mitochondria are very important for cell survival, as they have the ability to sequester 
large amounts of Ca2+. From in vitro studies [98] it can be inferred that mitochondria within 
intact neurons will act as temporary reversible stores of Ca2+, accumulating the cation when 
cytoplasmic Ca2+ is above a set point, and releasing the cation back to the cytoplasm when the 
plasma membrane Ca2+-ATPase succeeds in pumping down cytoplasmic Ca2+ to below the set 
point [96, 99]. For this cytoplasmic buffering to occur with no deleterious effects for the 
mitochondria and hence the cell, the time during which cytoplasmic Ca2+is above the set point 
must be brief, thus avoiding mitochondrial Ca2+ overload [96]. During stroke, electron 
microscope analyses show that Ca2+ accumulates in mitochondria very soon after global 
ischemia and this state persists for several hours [100]. Excessive and prolonged uptake of Ca2+ 
in mitochondria causes mitochondrial dysfunction [41, 96, 101], which is considered the 
primary event in neuron death due to excitotoxicity [41]. 
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Fig. 3. Excitotoxic signaling by overstimulation of the NMDA receptors. Major excitotoxic 
events promoted by extrasynaptic NMDAR activation. Cerebral ischemia elevates cytosolic 
Ca2+ levels through the stimulation of NMDARs. The calcium overload: a) activates calpains 
that inactivate of the Na+/Ca2+ exchanger (NCX3), b) induces mitochondrial disturbance 
that activate intrinsic apoptotic pathway and c) activates NOS that increases the NO 
production. Higher concentrations of nitric oxide can produce irreversible modifications of 
proteins, lipids and impairment of mitochondrial respiration. All of these processes trigger 
pathological mechanisms leading to neuronal death.  
Mitochondrial dysfunction as a consequence of prolonged accumulation of Ca2+ is 
considered a major source of free radicals that are generated after ischemia-reperfusion [102, 
103]. As a result of the mitochondrial dysfunction induced by the free Ca2+ cytosol 
accumulation, two events seem to play an important role in the death of neurons: the 
increase in the production of free radicals associated with a diminution of the antioxidant 
defences [102, 103], and the induction of the apoptotic cascade (Fig. 4) [104, 105]. 
Under physiological conditions, free radicals are generated at low levels and play 
important roles in signalling and metabolic pathways (106-108]. However, free radicals 
avidly interact with a large number of molecules including other small inorganic 
molecules as well as proteins, lipids, carbohydrates, and nucleic acids. Through such 
interactions, free radicals may irreversibly destroy or alter the function of the target 
molecule. Consequently, free radicals have been increasingly identified as major 
contributors to damage in biological organisms. The significance of free radicals as 
aggravating or primary factors in numerous pathologies is firmly established [109, 110]. 
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Importantly, free radicals are produced continually during normal oxidative metabolism, 
but there are counteracted by a sophisticated system of enzymes and non-enzymatic 
antioxidants which maintains physiological homeostasis [111](Fig. 5). Enzymatic 
components mainly comprise superoxide dismutases (SOD) [112], catalases [111], 
glutathione [113] glutathione reductase/glutathione peroxidases (GR/GPX) [114], and 
peroxiredoxins [115]. Also, small molecular non-enzymatic antioxidants are important in 
scavenging free radicals. These include ascorbic acid, pyruvate, α-tocopherol and 
glutathione, which are also involved in the detoxification of free radicals, provision of 




Fig. 4. Mitochondrial dysfuntion by disruption of calcium homeostasis leads to oxidative 
stress and apoptosis. Mitochondria are involved in both, the necrosis and the apoptotic 
pathways, which depend on the severity of the insult or nature of the signaling pathways. 
When cytosolic Ca2+ reaches non-physiological levels, the mitochondrial membrane may 
become more permeable, which causes release of cytochrome c and activation of the 
apoptotic pathway. Ca2+-induced mitochondria disturbance involves dysfunction of ETC, 
increased ROS and oxidative stress.  
When an imbalance occurs, either by increasing free radical formation or decreased anti-
oxidant defences, and the formation of free radicals exceeds the protective capacity of 
antioxidant systems, the accumulation of free radicals is known as a state of “oxidative 
stress” [116]. Oxidative stress is generally defined as an imbalance that favours the 
production of free radicals over their inactivation by antioxidant defence systems [117].  
www.intechopen.com
 




Fig. 5. Cellular reactions lead to oxidative damage of lipids, proteins and DNA via the 
Fenton reaction and their protection by main endogenous antioxidant enzymes (SOD, 
catalases and proxidaxes). The deleterious effects of ROS and RNS are controlled by 
antioxidant defences. Neurons are particularly vulnerable to oxidative stress owing to their 
high metabolic activity and oxygen consumption, which leads to high levels of ROS 
production, together with relatively low levels of endogenous antioxidant enzymes, 
particularly catalase. Moreover, the high lipid content of the brain can react with ROS to 
generate peroxyl radicals, leading to lipid oxidation of the neuronal membrane. The 
combination of these factors makes the CNS particularly vulnerable to oxidative damage.  
Oxidative stress induced by excitotoxicity is considered the main event leading to brain 
damage after cerebral ischemia [35, 103, 109]. The most important free radicals induced by 
excitotoxicity are molecular derivates of oxygen and oxide nitric. Owing to their high 
oxidizing power, the intermediate reduction states of oxygen are called reactive oxygen species 
(ROS) and nitrogen-containing oxidants are called reactive nitrogen species (RNS). ROS are 
small oxygen-derived molecules, including the superoxide anion radical (O2-), hydroxyl 
radical (OH·), and certain non-radicals that are either oxidizing agents or easily converted 
into radicals, such as hydrogen peroxide (H2O2) and the oxygen singlet (1O2). RNS are 
nitrogen-derived molecules, such as nitric oxide (NO), which has a relatively long half-life 
(approx. 1 s) and whose reactions with biological molecules are slow due to its very rapid 
diffusion into the blood and consequent inactivation by haemoglobin. NO is an important 
free radical because it combines with H2O2 and O2- to form OH and peroxynitrite 
(ONOO−), which is stable at an alkaline pH and fairly non-reactive, but it is readily 
protonated at cellular pH to peroxynitrous acid (ONOOH), which is very cytotoxic.  
Following early suggestions [118], free radicals and other small reactive molecules have 
emerged as important players in the cell mechanisms involved in the pathophysiology of 
strokes [35, 119-121]. Several lines of research indicate that oxidative stress is a primary 
mediator of neurologic injury following cerebral ischemia [103, 120, 121]. After cerebral 
ischemia and particularly reperfusion, robust oxidants are generated including superoxide 
and hydroxyl radicals, which overwhelm endogenous scavenging mechanisms [122, 123] 
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and are directly involved in the damage to cellular macromolecules, such as lipids, proteins, 
and nucleic acids, eventually leading to cell death [1,2] (Fig. 6). Re-oxygenation during 
reperfusion provides oxygen to sustain neuronal viability and also provides oxygen as a 
substrate for numerous enzymatic oxidation reactions that produce reactive oxidants. In 
addition, reflow after occlusion often causes an increase in oxygen to levels that cannot be 
utilized by mitochondria under normal physiological flow conditions. During reperfusion, 
perturbation of the antioxidative defence mechanisms is a result of the overproduction of 
oxygen radicals, inactivation of detoxification systems, consumption of antioxidants, and 
failure to adequately replenish antioxidants in the ischemic brain tissue [122-123].  
 
 
Fig. 6. ROS-mediated damage of cellular macromolecules may lead to neuron death. 
Excessive release of glutamate can trigger ROS increase. Antioxidant defences include 
several enzymes. In the healthy subjects, there is a balance between the production of 
antioxidants defences and of reactive species. When an imbalance occurs, either by 
increasing free radical formation and/or decreased anti-oxidant defences, and the formation 
of free radicals exceeds the protective capacity of antioxidant systems, the accumulation of 
free radicals leads to oxidative stress. 
The important role of free radicals in cell damage during stroke is emphasized by the fact 
that even delayed treatment with the use of antioxidants and inhibitors of free radical 
producing enzymes can be effective in experimental focal cerebral ischemia [124, 125]. In 
addition, the overproduction of radical-scavenging enzymes protects against stroke [126] 
and animals that are deficient in radical-scavenging enzymes are more susceptible to 
cerebral ischemic damage [127]. In addition, neuroprotection is evident in animal models 
where genes coding for enzymes that promote oxidative stress are knocked down or out, 
and where genes coding for antioxidant enzymes, e.g., superoxide dismutase (SOD) are 
over-expressed [44, 126].  
Increased levels of ROS and RNS generated extra- and intra-cellularly can, by various 
processes, initiate and promote neuron death during ischemic stroke. ROS and RNS can 
directly oxidize and damage macromolecules such as DNA, proteins, and lipids, 
culminating in neuron death[1, 2, 45-47]. ROS and RNS can also indirectly contribute to 
tissue damage by activating a number of cellular pathways resulting in the expression of 
stress-sensitive genes and proteins that cause oxidative injury [43]. 
Intracellular sources of ROS include the mitochondrial electron transport chain (ETC), 
xanthine oxidase, arachidonic acid, and NADPH oxidases. It is generally thought that 
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mitochondria are the primary source of ROS involved in oxidative stress induced after 
cerebral ischemia. Free radicals are produced in the mitochondria as by-products of 
respiratory chain reactions. While passing through the mitochondrial ETC, some electrons 
escape from the mitochondrial ETC, especially from complexes I and III, and react with O2 to 
form superoxide anion radicals (O2−) (Figure 7), which rapidly dismutate to H2O2 either 
spontaneously, particularly at low pH, or catalyzed by superoxide dismutase [128, 129]. 
Approximately 1%–2% of the molecular oxygen consumed during normal physiological 
respiration is converted into superoxide radicals [130]. 
 
 
Fig. 7. Cerebral ischemia and reperfusion generated reactive oxygen species by 
mitochondria and reactive nitrogen species by nitric oxide synthase. The generation of 
peroxynitrite (ONOO-), formed by the reaction of nitric oxide with superoxide anion, and 
subsequent hydroxil radical (OH•) production can directly damage lipids, proteins, and 
DNA and lead to neuron death. 
4. Oxidative stress in acute ischemic stroke 
Neurons are particularly vulnerable to oxidative stress owing to their high metabolic 
activity and oxygen consumption which lead to high levels of ROS production, together 
with relatively low levels of endogenous antioxidant enzymes, particularly catalase [131]. 
Moreover, the high lipid content of the brain can react with ROS to generate peroxyl radicals 
that lead to neuron membrane lipid oxidation [132]. The combination of these factors makes 
the CNS particularly vulnerable to oxidative damage [113].  
The primary source of free radical generation in cells during cerebral ischemia has been 
reported to be due to a decrease in mitochondria redox potential causing ROS production from 
the ETC, mainly at the level of cytochrome III [102, 103, 118, 130]. After ischemia, an excess of 
cytosolic free Ca2+ due to excitotoxicity may overload the mitochondrial proton circuit, which 
leads to failure in oxidation together with increased ROS production [102, 109]. 
Overproduction of ROS by mitochondria causes the impairment of the ETC, which in turn, 
leads to decreased ATP production, increased formation of free radicals, altered calcium 
homeostasis and mitochondrial dysfunction [130]. In the rat, transient middle cerebral artery 
occlusion (MCAO) induces ROS production and mitochondrial dysfunction, including the 
inactivity of ETC enzymes. The mitochondrial dysfunction is attenuated by treatment with an 
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antioxidant [133] or by the over-expression of mitochondrial Hsp70/Hsp75 [134], both of 
which decrease the ROS concentration. 
Although mitochondrial dysfunction has been considered as a major source of ROS, other 
excitotoxic pathways may also be important in inducing oxidative stress. Recently, it has 
been suggested that NADPH oxidase is the primary source of superoxide production 
following neuronal NMDAR activation [135]. All NADPH oxidase (NOX) family members 
are transmembrane proteins that transport electrons across biological membranes. In 
general, the electron acceptor is oxygen and the product of the electron transfer reaction is 
O2−. The biological function of NOX enzymes is therefore the generation of ROS. NADPH 
oxidase was originally described in neutrophils, but has subsequently been identified in 
many other cell types including neurons [136]. While NMDAR activation induces O2− 
production by NADPH oxidase, a near-complete absence of O2− production was observed 
in neurons lacking functional NADPH oxidase and in neurons in which NADPH oxidase 
function had been inhibited. Markedly reduced NMDA neurotoxicity was also observed 
under these conditions [137]. 
During the ischemic phase, some Ca2+-dependent enzymes, such as phospholipase A2 (PLA2) 
and cyclooxygenase (COX), produce oxygen free radicals. It has been shown that PLA2 levels 
increase in the brain within 2-30 min of ischemia [138]. The activation of PLA2 by Ca2+ results 
in the release of arachidonic acid from the phospholipids, which is further metabolized by 
cyclooxygenase to eicosanoids along with the production of free radicals [139]. 
Cyclooxygenase catalyzes the addition of two O2 molecules to arachidonic acid to produce the 
prostaglandina PGG2, which in turn is rapidly peroxidized to PGH2 with a simultaneous 
release of O2− [11, 140]. In addition, PLA2 activation generates lysophosphatides that alter 
membrane structures. Activation of PLA2 and cyclooxygenase generates free-radical species 
that overwhelm endogenous scavenging mechanisms, producing lipid peroxidation and 
membrane damage [2, 140]. 
During stroke, a high influx of Ca2+ through NMDA receptors may lead to the activation of 
nNOS and increase the production of NO [71, 77]. As described above, in neurons, NO is 
produced by neuronal NO synthase (nNOS), an enzyme tethered to the NMDA receptor 
complex by the postsynaptic density protein-95 (PSD95) [71]. During stroke NO production 
in the brain increases dramatically due to the activation of the neuronal and inducible 
isoforms of nitric oxide synthases [79]. The NO combines with H2O2 and O2- to form OH 
and peroxynitrite (ONOO−) [141]. which is generated at high levels and strongly contributes 
to ischemic brain damage [79]. After ischemia an important target of NO-induced ONOO− is 
mitochondria causing mitochondrial dysfunction and the consequent increased generation 
of oxygen free radicals leading to prompt dysfunction of cellular membranes causing 
necrosis. The ROS generated from the ETC can readily react with NO to form the highly 
reactive peroxynitrite, which can damage lipids, proteins and DNA [45-47, 79]. 
Mitochondrial Ca2+ overload, concomitant generation of free radicals, and depression of cell 
energy metabolism are thought to play important roles in the pathogenesis of ischemic brain 
damage [35, 36, 84, 101]. There is increasing evidence that NO is involved in the mechanisms 
of cerebral ischemia [78, 80]. After MCAO, the NO concentration in the ischemic area 
increases to micromolar levels. The surge in NO concentration can be inhibited by glutamate 
receptor antagonists, which show that increased production of NO is initiated by glutamate 
[78, 80]. In a clinical study in patients with acute ischemic stroke, increased NO metabolite 
in CSF was associated with greater brain injury and early neurological deterioration [142]. 
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The H2O2 formed from O2− has two possible fates: (i) conversion to hydroxyl radical (OH), 
the most reactive free radical produced in biological systems, by means of the Haber-Weiss 
reaction (H2O2 + O2− → O2 + OH + OH−) [143] which is favoured by iron ions in Fenton 
reaction (Fe2+ + H2O2 → Fe3+ + OH+ OH−) [144] or (ii) conversion to water by oxidation of 
the small tripeptide glutathione (GSH) via a reaction catalyzed by the enzyme glutathione 
peroxidase (GPX) (H2O2 + 2GSH → GSSG + 2H2O) or mutated to water and oxygen (H2O2→ 
H2O + ½ O2) by the catalase enzyme [106]. Reduction of the oxidized glutathione (GSSG) in 
a reaction catalyzed by glutathione reductase creates more GSH, which then converts more 
H2O2 to H2O (Fig. 8). About 1% of the mitochondrial ROS escape elimination by antioxidant 
defence mechanisms. The major contribution of mitochondria to cytosolic ROS comes from 
H2O2 escaping the GPX degradation in the matrix and by residual O2−, which can enter the 
cytosol via the porin (VDAC). The greatest oxidative cellular damage produced by 
superoxide, however, is derived from its participation in peroxinitrite (ONOO−) formation 
(O2− + NO → ONOO−) [141]. 
 
 
Fig. 8. The neurons, under physiological conditions, generate ATP mainly by mitochondrial 
phosphorylation via the electron transport chain (ETC). In this process, mainly complexes I 
and III carry out electrons to molecular oxygen, serving as the primary source of superoxide 
production. IMM: Inner mitochondrial membrane, OMM: Outer mitochondrial membrane. 
Oxidative/nitrosative stress may damage different cellular components, including oxidation 
of membrane lipids [132], essential cell proteins [145] and DNA [48] as well as initiating 
cascade reactions, which lead to mitochondrial dysfunction [109] caspase activation [146] 
and the activation of signal transduction pathways [14], which finally lead to neuron death. 
On the basis of experimental models, there is ample evidence for enhanced free radical 
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5. Apoptotic mechanisms after cerebral ischemia 
After ischemia, excitotoxicity can lead to apoptotic or necrotic cell death [65-68]. The route 
involved depends on the time elapsed, the intensity of the stimulus and the degree to which 
energy production is maintained. While necrosis occurs mainly in the earliest moments after 
the onset of ischemia in the core [2, 49-51], programmed cell death begins hours later and 
lasts for several days [104]. This delayed cell death occurs mainly in the penumbra and is 
thus temporally and spatially different from the rapid necrotic neuron death in the core. 
There are two general pathways for activation of apoptosis: the extrinsic and intrinsic 
pathways. Studies of tissue from patients and of animal models have shown that 
mitochondria-mediated apoptosis is the mode by which many neurons die after an acute 
stroke [105]. Oxidative stress and cytotoxic accumulation of intracellular Ca2+ initiate a 
series of cytoplasmic and cellular events, including the triggering of the intrinsic apoptotic 
pathway (Figure 9) [2, 105]. Increased ROS/RNS and intracellular free Ca2+ levels mediate 
induction/activation of pro-apoptotic proteins such as prostate apoptosis response 4 (Pr4), 
pro-apoptotic Bcl-2 members (Bax, Bad and others) and p53 [147], leading to changes in the 
mitochondrial membrane permeability (MMP) [148]. Proteins in the anti-apoptotic Bcl-2 
family as well as anti-apoptotic kinase Akt and ERK protect the mitochondrial integrity by 
inhibiting pro-apoptotic Bcl-2 family members. Following cerebral ischemia, several pro-
apoptotic members of the Bcl-2 family (tBid, Dp-5, Bim, Bax, Bak, and BAD) may antagonize 
the anti-apoptotic Bcl-2 family proteins to induce mitochondrial damage. Once the balance 
is shifted towards apoptosis, the mitochondria release apoptotic proteins such as cyt-c and 
AIF [104]. Alterations in expression of members of the Bcl-2 protein family, including 
increased expression of Bax and Bad, and reduced expression of Bcl-2 and Bcl-w, are found 
in the ischemic core and in the penumbra of the infarct [14]. A rapid translocation of 
cytosolic Bax to the mitochondria has been observed after cerebral ischemia [149]. After the 
opening of the mitochondrial pores, pro-apoptotic proteins are released into the cytosol; 
these include cytochrome c (cyt c) and Smac/DIABLO [149]. The release of cyt c and other 
pro-apoptotic proteins can trigger caspase activation and apoptosis. Once released into the 
cytosol from the mitochondrial intermembrane space, cyt c binds with apoptotic protein-
activating factor-1 (Apaf-1) and procaspase-9 to form an “apoptosome”, which actives 
caspase-9 and subsequently caspase-3. Activated caspase-3 dismantles a wide range of 
homeostatic, reparative and cytoskeletal proteins including nDNA repair enzymes, such as 
poly (ADP-ribose) polymerase (PARP), and activates caspase-activated DNase (CAD) [149] 
which cleaves nuclear DNA and leads to DNA damage and neuron cell death. Apoptotically 
damaged mitochondria also release other factors, such as AIF and EndoG, to facilitate DNA 
fragmentation and Smac/DIABLO to facilitate caspase activation [149]. There is a large body 
of evidence suggesting that cerebral ischemia can cause activation of caspases, certain types 
of protease that can cleave a larger number of cellular substrates [14, 105, 146]. Up 
regulation and activation of caspase-3 have been found to precede neuron death in focal and 
global cerebral ischemia [104]. 
Experiments involving manipulation of the molecular systems linked to the pathogenesis of 
apoptosis suggest that apoptosis is involved in neuron death following focal ischemic 
insults. Over-expression of human BCL-2 [150] reduces infarction in rodent brains subjected 
to focal ischemic insults. In addition, p53 knock-out transgenic mice also exhibit reduced 
brain vulnerability to focal ischemic insults. Interestingly, a greater protective effect was 
seen in heterozygous animals than in animals that were homozygous for the p53 null gene, 
which is consistent with some beneficial actions of p53 and some gene dose effect [151]. 
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Fig. 9. The intrinsic apoptosis pathway in neurons is initiated by moderate overactivation of 
glutamate receptors, oxidative stress and DNA damage. The apoptotic trigger often activate 
transcriptions factor such as p53 that induce the expression of the pro-apoptotic Bcl-2 family 
members bax and bad which increased permeability of the outer mitochondrial membrane 
and the subsequent release of cytochrome c to the cytosol. In the cytosol, cytochrome c binds 
to the apoptosome which then activitates the caspase cascade that, in turn, cleaves 
numerous protein substrates leading to the neuronal death. 
6. The role of calpains in strokes 
One of the key events induced after ischemia by Ca2+ overload is a massive activation (either 
directly or indirectly) of calpains, important contributors to excitotoxic cell death [152]. The 
calpain family consists of about 15 members of cellular cysteine proteases that are activated 
by calcium in the cytosol [153]. Calpains can modulate a variety of physiological processes 
[153]. Regulated activation of calpains in the CNS may be critical to synaptic function and 
memory formation. All calpains can act in two modes: under physiological conditions they 
undergo controlled activation (involving only a few molecules of calpain) whereas during 
sustained calcium overload under pathological conditions they undergo hyperactivation 
(involving all the available calpain molecules) [152]. 
Although neurons behave very differently in acute and chronic cerebral ischemia, there is a 
pervasive view that Ca2+-dependent calpain protease inhibitors are protective to varying 
degrees in animal models of stroke [154, 155]. Ample evidence documents the activation of 
calpains in brain ischemia and excitotoxic neuronal degeneration [152, 156]. Two 
mechanisms have recently been suggested which involve calpains as mediators of neuron 
death in strokes. In a rat model of focal ischemia, Ca2+-overload activated calpain cleavage 
of Na+/Ca2+ exchangers (NCX) thus precluding the possibility of restoring NCX [157], which 
are among the most potent regulators of Ca2+ concentrations in neuronal cells, and are a 
PARP
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contribute to Ca2+ cytosol accumulation during ischemia [87, 89]. Cleavage of NCX leads to 
an irreversible increase in the intracellular Ca2+ concentration. The inhibition of calpain 
prevents cleavage of NCX and prevents the secondary Ca2+ overload linked to neuronal 
demise [89]. So, calpain activation by excessive cytoplasmic Ca2+ can contribute to the 
mediation of cleavage of NCX and increase cytoplasmic calcium deregulation [157]. 
7. Anti-excitotoxic mechanisms and their potential as therapeutic targets 
In the treatment of acute cerebral ischemia, two primary therapeutic strategies are applied: 
(1) limitation of cerebral ischemia by early reperfusion after cerebral ischemia (the vascular 
approach), and (2) interference with the patho-biochemical cascade leading to ischemic 
damage (the neuroprotective approach) [158]  
7.1 The vascular approach 
After many years without any therapeutic treatment for strokes, and since seminal studies 
[6, 7] showed the existence of an ischemic penumbra where neurons maintain membrane 
potential for several hours or more after the onset of a stroke, recanalization therapies that 
aim to recover the flow of blood in the ischemic penumbra have been developed. 
The results of the intravenous application the tissue plasminogen activator (tPA) to reopen 
occluded blood vessels [159] led the US Food and Drug Administration to approve the use 
of tPA for treatment of acute ischemic stroke in 1996. The early recovery of blood flow in the 
cerebral ischemic region is the principal factor that prevents neuronal injury. Early 
recanalization with thrombolytic therapy clearly improves patient outcome after an acute 
stroke [159]. The use of tPA therapy when administered intravenously within the first 3 h, 
significantly improves patient outcome by approximately 30%. In addition, tPA is the only 
drug licensed and available for treatment of ischemic stroke that can lead to a recanalization 
of occluded vessels and to an improvement in clinical outcome. However, less than 5% of 
potentially eligible patient are currently being treated with tPA therapy in the USA or in 
Europe [160] and the use of tPA therapy remains limited. The reasons for this situation are 
complex, but in clinical practice the main obstacle is the narrow therapeutic time window, 
currently limited to 3 h, together with insufficient public knowledge of the stroke warning 
signs, the small number of centres able to administer thrombolysis on a 24-h basis and also 
some physicians’ excessive fear of haemorrhagic complications [161]. The use of tPA is 
associated with an increased risk of intracerebral haemorrhage (ICH) and mortality [162] 
and it requires sophisticated pre-treatment imaging [163].  
7.2 The neuroprotective approach 
The second major therapeutic approach, neuroprotection, aims: to rescue ischemic tissue and 
improve functional outcome by intervention on the ischemic cascade; and to reduce the 
intrinsic vulnerability of brain tissue to ischemia. Cellular neuroprotective approaches have 
focused mainly on blocking excitotoxicity, that is, neuron death triggered by the excitatory 
transmitter glutamate, and mediated by cytotoxic levels of calcium influx. Many experimental 
trials have demonstrated that many agents are effective in infarction volume reduction in 
animal models of stroke but have not been successfully translated to humans [164]. 
Neuroprotective strategies have failed to show clinical benefit despite promising laboratory 
results. Unfortunately, to date, none of tested neuroprotective agents has been shown to 
improve outcomes in phase III clinical trials [165]. All attempts to find effective neuroprotective 
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drugs for the treatment of strokes have failed to demonstrate unequivocal efficacy in clinical 
trials [166]. Because the brain is a complex organ that is capable of many intricate functions, it 
has proved difficult to develop drugs for the treatment of neurodegenerative disorders that do 
not interfere with the normal functioning of the nervous system. 
Preclinical research require rigorous attention to a variety of variables that may influence 
the outcome. The widely touted STAIR criteria represent constructive guidelines for 
preclinical testing [167] but, as experience has shown, have not increased the translational 
success. The failure to translate these strategies from the laboratory to clinical trials is a 
disappointment and many agents have been brought to clinical trial despite only modest or 
inconsistent preclinical evidence of neuroprotective efficacy. 
These recurrent clinical failures might be due to heterogeneous populations of stroke patients, 
drug-associated toxicity at the doses required for efficacy. They may also be due to low dose 
administration, irregular study design and inadequate statistical evaluation, the limited time 
window required for initiating treatment, or the lack of adequate CNS penetration across the 
blood–brain barrier (BBB) [165]. The future of neuroprotection is seen to lie in concentrating on 
the subgroup of patients with an existing penumbra, the combination of neuroprotection and 
thrombolysis and in prophylactic neuroprotection. Current therapeutic targets have focused 
on the preservation of the ischemic penumbra in the hope of improving clinical outcomes. 
Neuroprotective strategies may aid in prolonging time windows, thereby potentially 
increasing the number of patients who could benefit from reperfusion treatments. Reperfusion 
therapies are rapidly evolving and have been shown to improve clinical outcomes. There has 
been significant progress with successful reperfusion treatments associated with improved 
clinical outcomes. The use of neuroprotective agents to prolong time windows prior to 
reperfusion or to prevent reperfusion injury may present future therapeutic targets for the 
treatment of ischemic stroke. 
In recent years, over a thousand experimental and over four hundred clinical studies have 
been published. A close survey of the most extensively evaluated neuroprotection agents 
and their classes as well as the results of the clinical trials, have been published [164, 165, 
168]. The outcome at the clinical trial phase of some compounds for the treatment of acute 
ischemic stroke, are shown (Table 1) [18]. 
These considerations have led to the possibility of a future multidrug therapeutic approach 
that will probably have to include peptide growth factors for early induction of survival of 
signal transduction and recovery of translational competence, inhibition of calpain, 
inhibition of radical damage, and caspase inhibition. Rigorous studies to establish such an 
approach will require the evaluation of neurologic and histopathologic outcomes as well as 
of the molecular endpoints associated with each component to establish the role of each 
drug. Such a multi-factorial therapeutic approach to molecular injury mechanisms now 
appears essential for the development of substantially improved reperfusion. 
A new neuroprotective therapy opens interesting and hopeful perspectives. It is becoming 
increasingly clear that erythropoietin (Epo) is potentially neuroprotective in different 
models of brain injury [169-171]. Epo exerts its effects through the activation of the neuronal 
erythropoietin receptor (EpoR), part of the cytokine-receptor type I superfamily, where it 
acts as an anti-apoptotic, antioxidant, anti-inflammatory and neurothropic factor. Numerous 
preclinical findings and some clinical pilot studies [170-172] suggest that recombinant 
human Epo (rHuEpo) provides neuroprotection that may be beneficial in the treatment of 
patients suffering from ischemic stroke. Epo theoretically represents an ideal compound for 
neuroprotection, not only against strokes, but also against other brain disease. (See the 
chapter devoted to this issue in this book). 
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Compound Mechanism of action 
Inclusion 
period (h)
Outcome (Phase) Reasonb 
Selfotel NMDA receptor antagonist 6 Negative (III) Adverse events 




6 Negative (III) Lack of efficacy 
Eliprodil 
NMDA, polyamine site 
blocker 
6 Negative (II) Adverse events 
Magnesium 
sulphate 
NMDA, channel blocker 12 Negative (III) Lack of efficacy 
Cervene 
Kappa opioid receptor 
antagonist
6 Negative (III) Lack of efficacy 
Lubeluzole 
NOS inhibitor and Na+ 
channel blocker
8 Negative (III) Lack of efficacy 
Fosphenytoin Sodium channel blocker 6 Negative (III) Lack of efficacy 
BMS-204352 K+-channel blocker 6 Negative (III) Lack of efficacy 
Calcium 
antagonists 
Ca2+ channel antagonists 6–24 Negative  
 (Meta-analysis) Lack of efficacy 
Enlimomab Anti-ICAM antibody 6 Negative (III) Lack of efficacy 
and adverse events 
Citicoline Cell membrane stabilizer 24 Negative (III) Lack of efficacy 
Clomethiazole GABAA receptor mimetic 12 Negative (III) Lack of efficacy 
Tirilazad Lipid peroxidation inhibitor 4–24 Negative (III) 6 trials Lack of efficacy 
Ebselen Lipid peroxidation inhibitor 12–48 Negative (II) Lack of efficacy 
Repinotan 5-HT1A receptor antagonist 6 Negative (IIb) Lack of efficacy 
ONO-2506 Astrocyte modulating factor 6 Negative (II) Lack of efficacy in 
 futility analysis 
Trafermin Basic fibroblast growth factor 6 Negative (II/III) Lack of efficacy 
UK-279,276 Neutrophil inhibitory factor 6 Negative (II) Lack of efficacy in 
 Futility analysis 
a Abbreviations: BMS-204352, [35]-[+]-[5-chloro-2-methexyphenyl]-1,3-dihydro-3-fluoro-6-
[trifluoromethyl]-2H-indol-2-one; ICAM, intercellular adhesion molecule; NMDA, N-methyl-
Daspartate; 
NOS, nitric oxide synthase. 
b Lack of efficacy means that efficacy was not demonstrated. 
From Green A & Shuaib A. Drug Discovery Today 11(15/16) 681-694 (2006). 
Table 1. Some compounds that have failed in clinical evaluation for the treatment of acute 
ischaemic strokea 
8. Conclusions 
After the onset of a stroke, the disruptions to the blood flow in areas affected by vascular 
occlusion limit the delivery of oxygen and metabolic substrates to neurons causing ATP 
reduction and energy depletion. The glucose and oxygen deficit that occurs after severe 
vascular occlusion is the origin of the mechanisms that lead to cell death and consequently 
to cerebral injury. These mechanisms include: ionic imbalance, the release of excess 
glutamate in the extracellular space, a dramatic increase in intracellular calcium that in turn 
activates multiple intracellular death pathways such as mitochondrial dysfunction, and 
oxidative and nitrosative stress that finally cause neuron death. 
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During more than two decades, many neuroprotect drugs have emerged as potent inhibitors 
with different targets of the ischemic cascade in acute stroke. However, until now none of 
them succeeded in clinical trials. Despite the potential of Epo in animal models that 
enhanced resistance of the neurons to glutamate toxicity and other positive effects in 
different targets of ischemic cascade, Epo or its no erythropoietic variants as Neuro-EPO 
may be overcome by alternative non–traumatic administration methods, such as intranasal 
delivery. 
Many questions remain unanswered yet concerning this new molecule of Epo, which will 
try to be answered in the next chapter as we always learn from past mistakes in developing 
new drugs to stroke. A more biological basis is necessary in preclinical experimental 
research. This is the prerequisite to design an adequate molecule and administration 
delivery system. Finally, we want to give the reader a novel vision of how to face the acute 
treatment of the stroke with the application of Neuro-EPO via nasal. This will be the 
fundamental objective of the following chapter, in explaining the quick clinic application of 
this new molecule by nasal delivery for acute stroke therapy. 
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